Domainex to expand drug discovery services
And invest in its oncology pipeline in 2011
Domainex, a UK biotechnology firm, plans significant expansion of its medicinal chemistry and biology capabilities in 2011, which will involve relocating to larger laboratories in Cambridge and investing in new technologies. The company says this will allow it to provide better customer support and expand its discovery-phase oncology drug pipeline.
The first step in this expansion has been to hire George Buckley as business development manager, who joins the firm from Cresset, where he was sales manager.
Trevor Perrior, Domainex’s research director, said: ‘Domainex is entering a new phase in its development. Our service division is undergoing a significant expansion to support a number of new contracts, and our drug discovery division has advanced its first project, focused on the IKKε and TBK1 oncology and inflammation targets, to a point where we will seek to out-license the project in 2011.
‘Other targets in the Domainex pipeline, including a number of methyltransferases with important roles in epigenetics, will also benefit from increased investment and resources.’
